

Asst. Prof. KÜBRA ÇALIŞKAN

Personal Information

Office Phone: [+90 312 202 3226](tel:+903122023226)

Email: kubraibis@gazi.edu.tr

Other Email: kub.ibis1992@gmail.com

Web: <https://avesis.gazi.edu.tr/kubraibis>

International Researcher IDs

ScholarID: -cVg9HMAAAAJ

ORCID: 0000-0002-6898-0258

Publons / Web Of Science ResearcherID: AHA-8168-2022

ScopusID: 57204017714

Education Information

Doctorate, Gazi University, Sağlık Bilimleri Enstitüsü, Turkey 2015 - 2020

Undergraduate, Gazi University, Eczacılık Fakültesi, Turkey 2010 - 2015

Dissertations

Doctorate, Yeni izoksazol türevlerinin sentezi, karaciğer ve meme kanseri hücre hatlarına karşı sitotoksik etkilerinin incelenmesi, Gazi University, Sağlık Bilimleri Enstitüsü, 2020

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutical Chemistry

Academic Titles / Tasks

Lecturer PhD, Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri, 2021 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer**
Gedik M. E., Saatci O., Oberholtzer N., ÜNER M., Akbulut Caliskan O., Cetin M., Aras M., ÇALIŞKAN K., ÇALIŞKAN B., BANOĞLU E., et al.
Cancer research, vol.84, no.9, pp.1475-1490, 2024 (SCI-Expanded)
- Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors.**
Gür Maz Z. T., Koç B., Jordan P. M., İbiş K., Çalışkan B., Werz O., Banoğlu E.
ACS omega, vol.8, no.2, pp.2445-2454, 2023 (SCI-Expanded)
- The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool.**

- Lengerli D., Ibis K., Nural Y., Banoglu E.
Expert opinion on drug discovery, vol.17, no.11, pp.1209-1236, 2022 (SCI-Expanded)
- IV. **Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity**
Turanlı S., NALBAT E., LENGELİ D., İBİŞ K., Güntekin Ergün S., Akhan Güzelcan E., MUYAN M., Cetin-Atalay R., Çalıřkan B., BANOĐLU E.
ACS Omega, vol.7, no.41, pp.36206-36226, 2022 (SCI-Expanded)
- V. **Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells**
Ibis K., NALBAT E., ÇALIŐKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĐLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.221, 2021 (SCI-Expanded)
- VI. **Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents**
ÇALIŐKAN B., NALBAT E., Ibis K., Guzelcan E. A., ATALAY R., BANOĐLU E.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol.33, no.1, pp.1352-1361, 2018 (SCI-Expanded)

Refereed Congress / Symposium Publications in Proceedings

- I. **DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL IMIDAZOLIDINONE-THIAZOLE AMIDE HYBRIDS AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE**
İbiř K., Lengerli D., Jordan P. M., Çalıřkan B., Werz O., Banođlu E.
9th EFMC Young Medicinal Chemists' Symposium, Nice, France, 8 - 09 September 2022
- II. **KARACIĐER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PIPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK DEĐERLENDİRİLMESİ**
İbiř K., Nalbat E., Çalıřkan B., Atalay R., Banođlu E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 - 29 August 2022
- III. **Novel isoxazole- piperazine derivatives inhibit the stemness of HCC cells**
NALBAT E., İBİŐ K., ÇALIŐKAN B., BANOĐLU E., ATALAY M. V., ATALAY R.
AASLD-TASL Digital Hepatology Meeting, Ankara, Turkey, 15 January 2022, pp.5-6
- IV. **SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION OF NOVEL ISOXAZOLE-PIPERAZINE HYBRIDS**
ÇALIŐKAN B., Sinoplu E., İbiř K., AKHAN GÜZELCAN E., ATALAY R., BANOĐLU E.
RICT 2018, 4 - 06 July 2018
- V. **SYNTHESIS, CYTOTOXICITY AND STRUCTURE-ACTIVITYRELATIONSHIPS OF NOVEL ISOXAZOLE DERIVATIVES ASANTICANCER AGENTS**
İbiř K., ÇALIŐKAN B., AKHAN GÜZELCAN E., Sinoplu E., ATALAY R., BANOĐLU E.
RICT 2018, 4 - 06 July 2018
- VI. **Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges**
BANOĐLU E., ÇALIŐKAN B., GÜR MAZ Z. T., OLĐAÇ A., İBİŐ K., Akhan Güzelcam E., Sinoplu E., Garscha U., Gerstmeier J., ATALAY R., et al.
The 4th International Symposium on Pharmaceutical and Biomedical Sciences, Kumamoto, Japan, 17 March 2018

Supported Projects

ÇALIŐKAN K., KARATAŐ M., JORDAN P. M., BANOĐLU E., ÇALIŐKAN B., WERZ O., Project Supported by Higher Education Institutions, Dual FLAP/sEH İnhibitörlerinin Geliřtirilmesi Üzerine Çalıřmalar, 2023 - Continues
Banođlu E., Çalıřkan B., TUBITAK Project, Meme ve Karaciđer Kanserinin Tedavisi için PI3K/Akt Sinyal Yolunu Hedefleyen

Yeni Aday İlaç Molekül Geliştirme ve Ön klinik Çalışmaları, 2016 - 2019

Banoğlu E., Çalışkan B., TÜBİTAK Project, INVESTIGATIONS ON THE SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIPS AND MECHANISMS OF ACTION OF NOVEL ISOXAZOLE DERIVATIVES WITH POTENTIAL ANTICANCER ACTIVITY, 2015 - 2018

Patent

Banoğlu E., Çalışkan B., Muyan M., Atalay R., Erson Bensan A. E., Lengerli D., Güntekin S., Turanlı S., İbiş K., ANTİKANSER AKTİVİTEYE SAHİP YENİ VİSİNAL DİARİL HETEROSİKLİK BİLEŞİK TÜREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: TR 2019 14610 B , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Lim C., Cruz E., Vempati S., TW111113780-COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 111113780 , Standard Registration, 2022

Banoğlu E., Çalışkan B., İbiş K., Lengerli D., Şahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., JP2022-527677-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022-527677 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., KR10-2022-7020047-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2022-7020047 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., CN 202080091759.9 (2022110200431050)-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN 115279754 A (2022072000921700) , Standard Registration, 2022

Banoğlu E., Çalışkan B., İbiş K., Lengerli D., Şahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., EP20888312.4-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/20888312.4 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Vempati S., Lim C., Cruz E., PCT/US2022/024263 (WO2022/221194 A1) COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US22/24263 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., US17/776,767-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US17/776,767 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Lim C., Cruz E., Vempati S., COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US63173796 , 2021

Banoğlu E., Çalışkan B., Atalay R., Akhan Güzelcan E., İbiş K., ANTİKANSER AKTİVİTEYE SAHİP YENİ İZOKSAZOL TÜREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: 2017 19951 , Standard Registration, 2021

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS (US/PCT), Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US/2020/060588 , 2020

Metrics

Publication: 12

Citation (WoS): 58

Citation (Scopus): 82

H-Index (WoS): 3

H-Index (Scopus): 3